Kevin Outterson
Impact in
-
- Antibiotic Use and Resistance
- Molecular Medicine top 0.5%
- Antibiotic Resistance in Bacteria
Papers in
-
- Antibiotic Use and Resistance 41
-
- Antibiotic Resistance in Bacteria 13
- Co-authors
- Ursula TheuretzbacherAnders KarlénJohn RexAaron S. KesselheimChristine ÅrdalRamanan LaxminarayanNithima SumpraditManica Balasegaram
- Journals
- The Journal of Law Medicine & Ethics (7 papers)Health Affairs (6 papers)New England Journal of Medicine (6 papers)The Lancet Infectious Diseases (5 papers)Nature Reviews Drug Discovery (4 papers)
- Partner nations
- United StatesUnited KingdomNorway
In The Last Decade
Kevin Outterson
91 papers receiving 2.4k citations
Hit Papers
Peers
Comparison fields: 5 of 157
- Applied Microbiology and Biotechnology 766
- Molecular Medicine 661
- Microbiology 273
- Economics and Econometrics 551
- Pharmacology 154
Countries citing papers authored by Kevin Outterson
This map shows the geographic impact of Kevin Outterson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Outterson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Outterson more than expected).
Fields of papers citing papers by Kevin Outterson
This network shows the impact of papers produced by Kevin Outterson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Outterson. The network helps show where Kevin Outterson may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Kevin Outterson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 1 | |
| 5 | Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance Hit paper breakdown → | 2024 | 58 |
| 6 | Revitalizing the antibiotic pipeline: Stimulating innovation while driving sustainable use and global access | 2018 | 33 |
| 7 | Repairing the Broken Market for Antibiotic Innovation | 2015 | 2 |
| 8 | New Business Models for Sustainable Antibiotics | 2014 | 27 |
| 9 | Analytical Framework for Examining the Value of Antibacterial Products | 2014 | 36 |
| 10 | Plunging into Endless Difficulties: Medicaid and Coercion in National Federation of Independent Business v. Sebelius | 2013 | 1 |
| 11 | Deductions for Drug Ads? The Constitution Does Not Require Congress to Subsidize Direct-To-Consumer Prescription Drug Advertisements | 2012 | 2 |
| 12 | Agents Without Principals: Regulating the Duty of Loyalty for Nonprofit Corporations Through the Intermediate Sanctions Tax Regulations | 2012 | 1 |
| 13 | Fighting Antibiotic Resistance: Marrying New Financial Incentives to Meeting Public Health Goals | 2010 | 2 |
| 14 | Death from the Public Domain | 2009 | 1 |
| 15 | How Medicare Could Get Better Prices On Prescription Drugs | 2009 | 2 |
| 16 | 2009 | 1 | |
| 17 | Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets. | 2005 | 31 |
| 18 | The Vanishing Public Domain: Antibiotic Resistance, Pharmaceutical Innovation and Global Public Health | 2005 | 2 |
| 19 | Agony in the Antipodes: The Generic Drug Provisions of the Australia-U.S. Free Trade Agreement | 2005 | 7 |
| 20 | Free Trade Against Free Riders | 2004 | 4 |
About Kevin Outterson
Kevin Outterson is a scholar working on Applied Microbiology and Biotechnology, Molecular Medicine, Economics and Econometrics, Management of Technology and Innovation and Pharmacology, having authored 104 papers that have together received 2.5k indexed citations. Recurring topics across this work include Pharmaceutical Economics and Policy (61 papers), Antibiotic Use and Resistance (41 papers), Biosimilars and Bioanalytical Methods (17 papers), Pharmaceutical industry and healthcare (15 papers), Health Systems, Economic Evaluations, Quality of Life (14 papers), Antibiotic Resistance in Bacteria (13 papers), Intellectual Property and Patents (12 papers) and Pharmaceutical Quality and Counterfeiting (7 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (766 citations), Molecular Medicine (661 citations), Microbiology (273 citations), Economics and Econometrics (551 citations) and Pharmacology (154 citations). Kevin Outterson has collaborated with scholars based in United States, United Kingdom and Norway. Frequent co-authors include Ursula Theuretzbacher, Anders Karlén, John Rex, Aaron S. Kesselheim, Christine Årdal, Ramanan Laxminarayan, Nithima Sumpradit, Manica Balasegaram, David McAdams and John H. Powers. Their work appears in journals such as The Journal of Law Medicine & Ethics, Health Affairs, New England Journal of Medicine, The Lancet Infectious Diseases and Nature Reviews Drug Discovery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.